LIST OF PUBLICATIONS

Sheela ABRAHAM:


Helena ÅGERSTAM:


Philip BEER:


Ravi BHATIA:


Jason BIELAS:


Tim BRUEMMENDORF:


Debora CASOLARI:


Mhairi COPLAND:


Jorge CORTES:


Nick CROSS:


Yashodhara DASGUPTA:


Biagio DE ANGELIS:


**Caterina DE BENEDITTIS:**


**Josu DE LA FUENTE:**


**Michael DEININGER:**


**Massimo DELLEDONNE:**


**Marc DELORD:**


**Connie EAVES:**


**Anna EIRING:**


**Tariq ENVER:**


**Robert Peter GALE:**


**Paolo GALLIPOLI:**


**George GIOTOPoulos:**


Joëlle GUILHOT:


Emir HADZIJUSUFOVIC:


Benjamin HANFSTEIN:


Oliver HANTSCHEL:


Brian HUNTLY:


Qingfei JIANG:


Zeynep KALENDER:


Praveen KHANDELWAL:

Hawk KIM:

Alexander KOHLMANN:

Steffen KOSCHMIEDER:

Shaoguang LI:

Hanyang LIN:

Claire LUCAS:

Véronique MAGUER-SATTA:


François-Xavier MAHON:


Hemant MALHOTRA


• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 Apr 121: 4439-4442

Manuela MANCINI:


Susanne MATTHES-MARTIN:


Michael MAURO:


• Mauro MJ. T315I, more or less, predicts for major molecular response: the devil is in the details! Haematologica. 2013 May;98(5):665-6.

Markus MUSCHEN:

Charles MULLIGHAN:

Satu MUSTJOKI:

Miwako NARITA:
• Yamahira A, Narita M, Ishii K et al. Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene. Leuk Res. 2012 Dec;36(12):1541-6

Lucien NOENS:

Sukjoong OH:
Thomas O'HARE:


Sin Tiong ONG:


Kim ORCHARD:


Francesca PELLICANO:


Danilo PERROTTI:


Rocco PIAZZA:


**Jerald RADICH:**


• Stein AM, Bottino D, Modur V, et al. BCR–ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. *Clinical Cancer Research* 17:6815, 2011


**Feyruz RASSOOL:**


• Cramer K, Nieborowska-Skorska M, Scheibner K et al. "RAD52-dependent personalized synthetic lethality in tumors identified by genetic and epigenetic profiling"*(in press in Blood)*

**David ROSS:**


**Philippe ROUSSELOT:**


**Martin RUTHARDT:**


Anil SADARANGANI:


David SCHEINBERG:


Tomasz SKORSKI:


Simona SOVERINI:


Meinolf SUTTORP:

Ali TURHAN:


Jeffrey TYNER:


Paolo VIGNERI:


Richard VAN ETTEN:


Deborah WHITE:

- White, D.L., and Hughes, T.P. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. *J Clin Oncol.* 2012 Apr 1;30(10):1144-5
